Subsequent analysis of hind limbs revealed a reduced tumor burden 4-weeks post-injection in CD44-depleted conditions, with a 1132-fold lower signal detected in the sh#1-transfected model (n = 6, p = 0.033) and 1137-fold decrease observed in the sh#2-transfected model (n = 6, p = 0.047) relative to the shNT control (Fig. 4A). Here, CD44 is linked to neoplasm.